The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
SY-009 is a novel compound that inhibits sodium glucose cotransporter-1 (SGLT-1). The
preclinical and phase 1 clinical trial data support to carry out phase II clinical trial in
diabetes subjects.